双功能阻断：宫颈癌的一种新型免疫治疗方法。
Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.
机构信息
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
出版信息
Clin Cancer Res. 2022 Dec 15;28(24):5238-5240. doi: 10.1158/1078-0432.CCR-22-1779.
Abstract
SHR-1701, a bispecific fusion protein directed against PD-L1 and TGFβ, demonstrates promising clinical activity in advanced/recurrent cervical cancer. A recent study serves as a proof of principle that the TGFβ pathway may be successfully targeted, and that bispecific antibodies offer a novel therapeutic approach to do so. See related article by Feng et al., p. 5297.
摘要
SHR-1701 是一种针对 PD-L1 和 TGFβ 的双特异性融合蛋白，在晚期/复发性宫颈癌中显示出有前景的临床活性。最近的一项研究证明了 TGFβ 通路是可以成功靶向的，并且双特异性抗体为实现这一目标提供了一种新的治疗方法。详见 Feng 等人的相关文章，第 5297 页。
相似文献
1
Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.双功能阻断：宫颈癌的一种新型免疫治疗方法。
Clin Cancer Res. 2022 Dec 15;28(24):5238-5240. doi: 10.1158/1078-0432.CCR-22-1779.
2
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy.双特异性抗体靶向 TGF-β 和 PD-L1 用于协同癌症免疫治疗。
Front Immunol. 2023 Jul 13;14:1196970. doi: 10.3389/fimmu.2023.1196970. eCollection 2023.
3
Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer.调控转化生长因子-β信号通路以优化宫颈癌免疫治疗
Biomed Pharmacother. 2023 Oct;166:115355. doi: 10.1016/j.biopha.2023.115355. Epub 2023 Aug 28.
4
Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.阻断 PD-1/PD-L1 可通过 ADCC 增强的抗 B7-H3/PD-1 融合蛋白来激发免疫激活和细胞毒性。
Int Immunopharmacol. 2020 Jul;84:106584. doi: 10.1016/j.intimp.2020.106584. Epub 2020 May 15.
5
SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study.SHR-1701，一种靶向程序性死亡配体1（PD-L1）和转化生长因子β（TGFβ）的双功能融合蛋白，用于复发性或转移性宫颈癌：一项I期研究的临床扩展队列
Clin Cancer Res. 2022 Dec 15;28(24):5297-5305. doi: 10.1158/1078-0432.CCR-22-0346.
6
Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer.不同免疫疗法联合 PD-1/PD-L1 阻断在宫颈癌中的治疗策略。
Drug Des Devel Ther. 2022 Sep 9;16:3055-3070. doi: 10.2147/DDDT.S374672. eCollection 2022.
7
Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy.将肿瘤 PD-L1 转化为 4-1BB 激动剂，以实现更安全、更有效的癌症免疫治疗。
Cancer Discov. 2022 May 2;12(5):1184-1186. doi: 10.1158/2159-8290.CD-22-0219.
8
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.口服 STING 激动剂 MSA-2 与抗 TGF-β/PD-L1 双特异性抗体 YM101 联合应用：一种针对非炎症性肿瘤的新型免疫鸡尾酒疗法。
J Hematol Oncol. 2022 Oct 8;15(1):142. doi: 10.1186/s13045-022-01363-8.
9
Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.双特异性抗体方法提高黑色素瘤选择性 PD-L1 免疫检查点阻断。
J Invest Dermatol. 2019 Nov;139(11):2343-2351.e3. doi: 10.1016/j.jid.2019.01.038. Epub 2019 May 23.
10
Effect of immunotherapy on the immune microenvironment in advanced recurrent cervical cancer.免疫疗法对晚期复发性宫颈癌免疫微环境的影响。
Int Immunopharmacol. 2022 May;106:108630. doi: 10.1016/j.intimp.2022.108630. Epub 2022 Feb 18.
引用本文的文献
1
Comprehensive overview of antibody drug-related clinical studies in gynecology: insights from ClinicalTrials.gov.妇科抗体药物相关临床研究综述：来自ClinicalTrials.gov的见解
Front Med (Lausanne). 2025 May 9;12:1521587. doi: 10.3389/fmed.2025.1521587. eCollection 2025.
2
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial.SHR-1701联合法米替尼治疗既往治疗过的晚期胆管癌或胰腺导管腺癌患者的临床和生物标志物分析：一项II期试验
Signal Transduct Target Ther. 2024 Dec 13;9(1):347. doi: 10.1038/s41392-024-02052-3.
3
TGF-beta signal transduction: biology, function and therapy for diseases.转化生长因子-β信号转导：生物学、功能及疾病治疗
Mol Biomed. 2022 Dec 19;3(1):45. doi: 10.1186/s43556-022-00109-9.
本文引用的文献
1
SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study.SHR-1701，一种靶向程序性死亡配体1（PD-L1）和转化生长因子β（TGFβ）的双功能融合蛋白，用于复发性或转移性宫颈癌：一项I期研究的临床扩展队列
Clin Cancer Res. 2022 Dec 15;28(24):5297-5305. doi: 10.1158/1078-0432.CCR-22-0346.
2
Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer.抗 PD-L1/TGF-βR 融合蛋白（SHR-1701）克服了肺癌中淋巴细胞恢复紊乱引起的对 PD-1/PD-L1 抑制剂的耐药性。
Cancer Commun (Lond). 2022 Jan;42(1):17-36. doi: 10.1002/cac2.12244. Epub 2022 Jan 3.
3
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.派姆单抗治疗持续性、复发性或转移性宫颈癌。
N Engl J Med. 2021 Nov 11;385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18.
4
Novel therapies emerging in oncology to target the TGF-β pathway.肿瘤学中新兴的靶向 TGF-β 通路的新型疗法。
J Hematol Oncol. 2021 Apr 6;14(1):55. doi: 10.1186/s13045-021-01053-x.
5
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.YM101：一种同时靶向 TGF-β和 PD-L1 的双特异性抗体的构建、表达及增强的抗肿瘤活性。
J Hematol Oncol. 2021 Feb 16;14(1):27. doi: 10.1186/s13045-021-01045-x.
6
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.双功能融合蛋白靶向 TGF-β 和 PD-L1 的 Bintrafusp alfa 在人乳头瘤病毒相关恶性肿瘤患者中的应用。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001395.
7
Cancer immunotherapy via targeted TGF-β signalling blockade in T cells.通过靶向T细胞中的转化生长因子-β信号传导阻滞进行癌症免疫治疗。
Nature. 2020 Nov;587(7832):121-125. doi: 10.1038/s41586-020-2850-3. Epub 2020 Oct 21.
8
On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?靶向抗转化生长因子-β疗法在临床癌症治疗中未取得成功：尚存哪些挑战？
Front Cell Dev Biol. 2020 Jul 8;8:605. doi: 10.3389/fcell.2020.00605. eCollection 2020.
9
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.尼伏鲁单抗单药治疗复发性或转移性宫颈癌、阴道癌或外阴癌的安全性和疗效：来自 I/II 期 CheckMate 358 试验的结果。
J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5.
10
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation.白细胞介素-10 家族细胞因子白细胞介素-10 和白细胞介素-22：从基础科学到临床转化。
Immunity. 2019 Apr 16;50(4):871-891. doi: 10.1016/j.immuni.2019.03.020.
Zotero 插件